Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Characteristic of patients

From: Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells

No. Age/sex Diagnose WBC (109/L) HGB (g/L) PLT (109/L) BCR/ABL Treatment Time of disease (month) Survival
P1 43 Y/M CML-CP 290 72 931 Positive Imatinib 11 Yes
P2 42 Y/F CML-CP 282 77 673 Positive Imatinib 11 Yes
P3 32 Y/F CML-CP 34 131 505 Positive Imatinib 10 Yes
P4 33 Y/M CML-CP 165 85 396 Positive Dasatinib 10 Yes
P5 27 Y/M CML-CP 288 68 560 Positive Imatinib 9 Yes
P6 63 Y/M CML-AP 320 77 887 Positive Imatinib 21 No
  1. P patient; Y year; M male; F female; CML-CP chronic myelogenous leukemia-chronic phase; CML-AP chronic myelogenous leukemia-acute phase; WBC white blood cells; HGB hemoglobin; PLT platelet